Publications by authors named "Bridget Giarusso"
Background: The treatment goal for recurrent malignant gliomas centers on disease stabilization while minimizing therapy-related side effects. Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective.
Methods: This phase I study was performed using metronomic temozolomide (mTMZ) at 25 or 50 mg/m/day continuously in 42-day cycles.